Publication: Glycated Albumin Measurement Using an Electrochemical Aptasensor for Screening and Monitoring of Diabetes Mellitus
Issued Date
2019-11-01
Resource Type
ISSN
15214109
10400397
10400397
Other identifier(s)
2-s2.0-85069721005
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Electroanalysis. Vol.31, No.11 (2019), 2254-2261
Suggested Citation
Sasinee Bunyarataphan, Tararaj Dharakul, Suthat Fucharoen, Kittiphong Paiboonsukwong, Deanpen Japrung Glycated Albumin Measurement Using an Electrochemical Aptasensor for Screening and Monitoring of Diabetes Mellitus. Electroanalysis. Vol.31, No.11 (2019), 2254-2261. doi:10.1002/elan.201900264 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/50550
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Glycated Albumin Measurement Using an Electrochemical Aptasensor for Screening and Monitoring of Diabetes Mellitus
Abstract
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Glycated albumin (GHSA) is a medium-term glycaemic control marker of diabetes, which can be used as an alternative to or together with glycated haemoglobin (HbA1c). Currently available methods for the measurement of GHSA are limited in clinical practice because they involve slow and cumbersome processes of sample preparation, proteolytic digestion, and thermal incubation, and they suffer from limited analytical performance, and/or a lack of normalization to total albumin (HSA) levels. In this paper, we developed a simple electrochemical biosensor to measure GHSA values based on two DNA aptamers that specifically bind to GHSA and HSA. We used square wave voltammetry (SWV) to measure binding of the target proteins to their specific biotinylated aptamers, which had been immobilised on separate streptavidin (STR)-modified screen-printed carbon electrodes (SPCEs), in the presence of the redox mediator ferricyanide (Fe(CN)63−). This electrochemical aptasensing system had a detection limit of 3 ng/ml for GHSA and 0.2 μg/ml for HSA. The results exhibited high selectivity for GHSA over other molecules present in the blood. The developed sensor was able to measure the amount of GHSA in plasma samples. A statistically significant difference was observed in the elevated plasma GHSA levels in diabetic versus non-diabetic patients. Moreover, the trends in these GHSA levels were consistent with those obtained using the HbA1c test. The sensing system reported herein could be applied as a point-of-care-testing (POCT) device for measurements of clinically relevant GHSA values.